Becton Dickinson 2026 Q2 EPS Guidance Increase Highlights Company Outlook

BD explains that modest EPS leverage in FY2027 starts from a low-single-digit revenue growth baseline and will be supported by pricing actions and BD Excellence productivity, while offsetting the Alaris headwind. The company links product momentum across growth platforms—APM/Alaris connectivity, tissue regeneration, pharmacy automation, biologics, Connected Care, and PureWick—to a favorable mix and earnings trajectory over the next 12–18 months.

Sources used

BDX2026 Q3

Research questionWhat does modest EPS leverage in 2027 mean, and what product drivers are expected over the next 12 to 18 months?

BD is making significant advancements in biologic drug delivery and patient monitoring to enhance safety and care quality through technological innovation and operational excellence.

Sources used

BDX2026 Q2

Research questionHow is BD progressing in the biologic drug delivery and monitoring sectors to advance patient care and safety?

🚀 BD is harnessing AI to boost innovation, operational efficiency, and financial performance in 2025, transforming healthcare technology and internal processes. 🤖💼

Sources used

BDX2 docs

Research questionAI in finance

Yard House’s menu appeal and group-friendly atmosphere helped drive strong quarterly sales, while Cheddar’s gains reflect food and operational improvements. Darden says Yard House’s smaller prototype can lower construction costs while preserving its $10.5 million average unit volume, but did not disclose a specific return target. The brands have distinct long-term growth ambitions: higher-single-digit unit growth for Yard House and mid-single-digit growth for Cheddar’s.

Sources used

DRI2027 Q1

Research questionWhat is driving the performance of Cheddar's and Yard House, what returns are expected from investments such as Yard House's smaller prototype, and what are the brands' long-term unit-growth ambitions?

Cintas raised its FY2027 incremental-margin outlook to 32%–34% and expects results in the range’s upper half, while cautioning that quarterly progress will be uneven. Workday comparisons, a demanding Q4 comparison, energy assumptions, and cost controls are key factors shaping the outlook; guidance also excludes UniFirst-related transaction costs and assumes no further acquisitions.

Sources used

CTAS2027 Q1

Research questionWhat is the expected cadence of margins for the rest of the year, and are there notable quarterly comparisons or other factors that could affect it?

Oracle’s customer prepayments, customer-provided hardware, and supplier financing can reduce how much cash Oracle must advance as RPO grows. These models change the timing and source of funding, not the need to build capacity. Management expects strong cash generation from projects after ramp-up, but gave no timeline for positive free cash flow and emphasized that infrastructure margins still depend on pricing, costs, and operating efficiency.

Sources used

ORCL2027 Q1

Research questionHow are Oracle's prepayment, bring-your-own-hardware, and supplier-financing models changing the relationship between RPO growth, CapEx, free cash flow, and infrastructure margins?

AutoZone outlines a store-maturation-driven ROIC story, highlighting zero ROIC in the first year and a path to above 20% by year six, with ~15% by year four. The majority of near-term ROIC gains come from UDS customers through faster delivery and expanded inventory, while national accounts offer longer-term upside but without separate ROIC targets disclosed.

Sources used

AZO2026 Q4

Research questionWhat did management say about ROIC by commercial segments?

Broadcom outlines a 2027–2028 gigawatt roadmap totaling about 30 GW, with AI semiconductor revenue of roughly $115B in 2027 and $230B in 2028. The implied revenue per roadmap GW is about $11.5B, while deployed content per GW remains in the $20–$30B range, signaling growth from higher gigawatt volumes as XPUs evolve.

Sources used

AVGO2026 Q3

Research questionCan you confirm the 2027–2028 gigawatt projections and discuss the implied revenue per gigawatt and its trend as XPUs evolve?

Medtronic reports robust Q1 2027 base business outside CAS, led by CRM, CST, and Surgical, with Altaviva offsetting SNM softness. The Cornerstone investment is a $700 million global initiative driving long-term growth, but near-term revenue timing is not disclosed, and management reduced the operating-margin expansion guidance by about 10 bps to fund reinvestments.

Sources used

MDT2027 Q1

Research questionPlease provide an update on Medtronic's base business excluding CAS, including Altaviva performance, plus details on the Cornerstone deal (timing of revenue impact in base Surgical, contract structure, geographic scope including whether the U.S. is included), and the margin guidance change (clarify the rationale behind lowering the operating profit margin expansion guidance by about 10 basis points)?

Cencora reports approximately 7% core growth in Q2 2026, suggesting underlying performance remains within its long-term framework despite WAC/IRA headwinds and customer losses. Management trimmed fiscal 2026 revenue guidance to 4-6%, but maintains a resilient long-term operating-income outlook supported by margin gains from mail-order conversions and ongoing OneOncology integration.

Sources used

COR2026 Q2

Research questionWhat is the impact on long-term revenue and operating income growth from WAC/IRA adjustments, the loss of the oncology and grocery customers, and faster brand conversions at the large mail-order customer, given the reported core growth near 7%?

International growth remained broad-based and resilient amid regional conflicts, with limited near-term impact and a positive, backlog-supported outlook that could soften if conditions persist.

Sources used

MRSH2026 Q2

Research questionWhat did management say about International growth amid regional conflicts?